This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised
by Zacks Equity Research
Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
by Zacks Equity Research
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
by Zacks Equity Research
Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.
Achillion (ACHN) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) reported a loss of 15 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had reported a loss of 13 cents per share.
BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session
by Zacks Equity Research
BioTime, Inc. (BTX) was above 7% in the last trading session.